Trials / Withdrawn
WithdrawnNCT03044379
Dapivirine Gel Rectal Safety and PK Study
A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- International Partnership for Microbicides, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Dapivirine Gel Rectal Safety and PK Study
Detailed description
A Randomized, Double Blind, Placebo-Controlled Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapivirine gel (0.05%) | MTN-026/IPM 038 will use the HTI pre-filled applicator, the same applicator that has been utilized in other rectal studies. |
| OTHER | Universal HEC placebo gel |
Timeline
- Start date
- 2015-09-29
- Primary completion
- 2017-09-01
- Completion
- 2017-11-01
- First posted
- 2017-02-07
- Last updated
- 2017-02-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03044379. Inclusion in this directory is not an endorsement.